US 12,168,780 B2
T cell receptor-deficient t cell compositions
Charles L. Sentman, Grantham, NH (US)
Assigned to TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US)
Filed by TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US)
Filed on May 12, 2020, as Appl. No. 16/872,438.
Application 16/872,438 is a division of application No. 15/966,103, filed on Apr. 30, 2018, granted, now 10,689,619.
Application 15/966,103 is a division of application No. 14/934,256, filed on Nov. 6, 2015, granted, now 9,957,480, issued on May 1, 2018.
Application 14/934,256 is a division of application No. 13/502,978, granted, now 9,181,527, issued on Nov. 10, 2015, previously published as PCT/US2010/054846, filed on Oct. 29, 2010.
Claims priority of provisional application 61/255,980, filed on Oct. 29, 2009.
Prior Publication US 2020/0339951 A1, Oct. 29, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01); A61K 35/12 (2015.01)
CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 2035/124 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/585 (2013.01); C12N 2501/515 (2013.01); C12N 2510/02 (2013.01); C12N 2511/00 (2013.01)] 5 Claims
 
1. A method of treating cancer in a human subject in need thereof, optionally a histoincompatible human recipient, which comprises administering a composition comprising a recombinant primary human T cell or progeny thereof, which primary human T cell or progeny thereof:
(i) has been modified to functionally impair and/or to reduce expression of the endogenous T cell receptor (TCR), and
(ii) has been further modified to express at least one functional exogenous non-TCR chimeric receptor comprising:
(1) at least one ligand binding domain which binds to a ligand expressed by human cancer cells of the treated subject and
(2) at least one signaling domain.